084650 — Labgenomics Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for Labgenomics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	33,175	119,478	202,407	144,773	73,127
Cost of Revenue
Gross Profit	13,389	71,750	125,411	96,767	32,394
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	32,400	66,210	97,944	78,567	79,921
Operating Profit	776	53,268	104,463	66,206	-6,794
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,075	51,822	109,132	63,393	-7,085
Provision for Income Taxes
Net Income After Taxes	962	42,764	83,855	47,926	-5,246
Minority Interest
Net Income Before Extraordinary Items
Net Income	962	42,766	83,855	48,397	-4,674
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	962	42,766	83,855	48,397	-4,674
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	19.7	670	1,246	715	-74.4
Dividends per Share